Prophylactic dendritic cell vaccination in antitumor immune response and tumor growth in a breast cancer mouse model




Cancer; Dendritic Cells; Vaccination; Immunotherapy; Tumor immunity.


Dendritic cell vaccines have demonstrated promising results for poorly immunogenic tumors, which may promote the generation of better immune responses in the tumor microenvironment. However, the vaccine has little been evaluated as a prophylactic option. Therefore, this study evaluates the influence of prophylactic dendritic cell vaccination on the antitumor immune response in the tumor microenvironment and on tumor growth, in an experimental model with breast cancer induced by 4T1. Therefore, Balb/c mice were separated into a vaccinated group and an unvaccinated group. Dendritic cell vaccine was differentiated and matured ex vivo from bone marrow. During the experimental period, the tumor volumes were checked periodically. The tumors were evaluated for immune cells (helper T lymphocytes and cytotoxic T lymphocytes), helper T cells (Th1, Th2, Th17, and Treg), TNF-α, and IFN-γ synthesis by Th1 and cytotoxic T lymphocytes. The vaccinated group had decreased tumor volume (14.0, 0-131.7) compared to the unvaccinated group (89.59, 0.1250-459.6) (p=0.0421). The Th1, Th2, Th17, Treg, cytotoxic T subtypes, including TNF-α and IFN-γ produced by Th1 and T cytotoxic, showed a significant increase in the vaccinated group, as did the balance of Th1/Th2 and Th1/Treg. The results showed that prophylactic vaccination with dendritic cells showed a considerable antitumor effect in the studied model by promoting an increase in the activation of important cells in the immune response and a reduction in tumor volume. The data provide evidence for timely activation of immune surveillance in the absence of tumor burden.


Ahrends, T., Busselaar, J., Severson, T. M., Bąbała, N., de Vries, E., Bovens, A., Wessels, L., van Leeuwen, F., & Borst, J. (2019). CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities. Nature Communications, 10(1).

Aly, H. A. A. (2012). Cancer therapy and vaccination. Journal of Immunological Methods, 382(1–2), 1–23.

Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014). Clinical use of dendritic cells for cancer therapy. The Lancet Oncology, 15(7), e257–e267.

Balkwill, F. (2011). The Inflammatory Tissue Microenvironment and the Early Stages of Malignancy. In Pre-Invasive Disease: Pathogenesis and Clinical Management (pp. 21–29). Springer New York.

Balkwill, F. R. (2012). The chemokine system and cancer. The Journal of Pathology, 226(2), 148–157.

Banchereau, J., & Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature, 392(6673), 245–252.

Bauer, C., Dauer, M., Saraj, S., Schnurr, M., Bauernfeind, F., Sterzik, A., Junkmann, J., Jakl, V., Kiefl, R., Oduncu, F., Emmerich, B., Mayr, D., Mussack, T.,

Bruns, C., Rüttinger, D., Conrad, C., Jauch, K.-W., Endres, S., & Eigler, A. (2011). Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunology, Immunotherapy, 60(8), 1097–1107.

Burke, J. D., & Young, H. A. (2019). IFN-Γ: A cytokine at the right time, is in the right place. In Seminars in Immunology (Vol. 43). Academic Press.

Burnet, F. M. (1970). The concept of immunological surveillance. In Progress in experimental tumor research. Fortschritte der experimentellen Tumorforschung. Progres de la recherche experimentale des tumeurs.

Chemin, K., Gerstner, C., & Malmström, V. (2019). Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation—Lessons From Rheumatoid Arthritis. Frontiers in Immunology, 10.

Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005). Primary Antitumor Immune Response Mediated by CD4+ T Cells. Immunity, 22(3), 371–383.

Cunha, L. L., Morari, E. C., Nonogaki, S., Bufalo, N. E., da Assumpção, L. V. M., Soares, F. A., Vassallo, J., & Ward, L. S. (2020). RORγt may Influence the Microenvironment of Thyroid Cancer Predicting Favorable Prognosis. Scientific Reports, 10(1), 4142.

da Cunha, A., Antoniazi Michelin, M., & Cândido Murta, E. F. (2016). Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. Immunology Letters.

Drake, C. G. (2011). Update on Prostate Cancer Vaccines. The Cancer Journal, 17(5), 294–299.

Durgeau, A., Virk, Y., Corgnac, S., & Mami-Chouaib, F. (2018). Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. In Frontiers in Immunology (Vol. 9, Issue JAN). Frontiers Media S.A.

Egberts, J. H., Cloosters, V., Noack, A., Schniewind, B., Thon, L., Klose, S., Kettler, B., Von Forstner, C., Kneitz, C., Tepel, J., Adam, D., Wajant, H., Kalthoff, H., & Trauzold, A. (2008). Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Research.

Farhood, B., Najafi, M., & Mortezaee, K. (2019). CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. In Journal of Cellular Physiology (Vol. 234, Issue 6, pp. 8509–8521). Wiley-Liss Inc.

Fong, L., Brockstedt, D., Benike, C., Wu, L., & Engleman, E. G. (2001). Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients. The Journal of Immunology, 166(6), 4254–4259.

Fu, C., & Jiang, A. (2018). Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. In Frontiers in immunology (Vol. 9, p. 3059). NLM (Medline).

Hong, X., Dong, T., Hu, J., Yi, T., Li, W., Zhang, Z., Lin, S., & Niu, W. (2013). Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. International Journal of Colorectal Disease, 28(1), 25–33.

Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020). Roles of IFN-γin tumor progression and regression: A review. In Biomarker Research (Vol. 8, Issue 1). BioMed Central Ltd.

Kachler, K., Holzinger, C., Trufa, D. I., Sirbu, H., & Finotto, S. (2018). The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma. OncoImmunology.

Kandalaft, L. E., Powell, Jr., D. J., Chiang, C. L., Tanyi, J., Kim, S., Bosch, M., Montone, K., Mick, R., Levine, B. L., Torigian, D. A., June, C. H., & Coukos, G. (2013). Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology, 2(1), e22664.

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., & Schellhammer, P. F. (2010). Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine, 363(5), 411–422.

Koido, S., Kashiwaba, M., Chen, D., Gendler, S., Kufe, D., & Gong, J. (2000). Induction of Antitumor Immunity by Vaccination of Dendritic Cells Transfected with MUC1 RNA. The Journal of Immunology, 165(10), 5713–5719.

Korkaya, H., Liu, S., & Wicha, M. S. (2011). Breast cancer stem cells, cytokine networks, and the tumor microenvironment. The Journal of Clinical Investigation, 121(10), 3804–3809.

Lanzavecchia, A., & Sallusto, F. (2005). Understanding the generation and function of memory T cell subsets. In Current Opinion in Immunology.

Lee, H. L., Jang, J. W., Lee, S. W., Yoo, S. H., Kwon, J. H., Nam, S. W., Bae, S. H., Choi, J. Y., Han, N. I., & Yoon, S. K. (2019). Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Scientific Reports, 9(1), 3260.

Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020). Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. Journal of Experimental Medicine, 217(8).

Liudahl, S. M., & Coussens, L. M. (2017). To Help or To Harm: Dynamic Roles of CD4+ T Helper Cells in Solid Tumor Microenvironments. In Immunology: Immunotoxicology, Immunopathology, and Immunotherapy.

Lokhov, P. G., & Balashova, E. E. (2010). Cellular Cancer Vaccines: an Update on the Development of Vaccines Generated from Cell Surface Antigens. Journal of Cancer, 230–241.

Lopes, A. M. M., Michelin, M. A., & Murta, E. F. C. (2017). Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions. Oncology Letters.

Lurje, I., Hammerich, L., & Tacke, F. (2020). Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: Implications for prevention and therapy of liver cancer. In International Journal of Molecular Sciences (Vol. 21, Issue 19, pp. 1–25). MDPI AG.

Maccalli, C., Parmiani, G., & Ferrone, S. (2017). Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Immunological Investigations, 46(3), 221–238.

Mahmoud, S., Lee, A., Ellis, I., & Green, A. R. (2012). Cd8+ T lymphocytes infiltrating breast cancer a promising new prognostic marker? OncoImmunology.

Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011). Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology.

Markov, O. V., Mironova, N. L., Sennikov, S. V., Vlassov, V. V., & Zenkova, M. A. (2015). Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma. PLOS ONE, 10(9), e0136911.

Martínez-Lostao, L., Anel, A., & Pardo, J. (2015). How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clinical Cancer Research.

Matheoud, D., Perié, L., Hoeffel, G., Vimeux, L., Parent, I., Marañón, C., Bourdoncle, P., Renia, L., Prevost-Blondel, A., Lucas, B., Feuillet, V., & Hosmalin, A. (2010). Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo. Blood, 115(22), 4412–4420.

Mathis, D., & Benoist, C. (2004). Back to Central Tolerance. Immunity, 20(5), 509–516.

Matias, B. F., De Oliveira, T. M., Rodrigues, C. M., Abdalla, D. R., Montes, L., Murta, E. F. C., & Michelin, M. A. (2013). Influence of Immunotherapy with Autologous Dendritic Cells on Innate and Adaptive Immune Response in Cancer. Clinical Medicine Insights: Oncology, 7, CMO.S12268.

Mercogliano, M. F., Bruni, S., Elizalde, P. V., & Schillaci, R. (2020). Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer. In Frontiers in Oncology.

O’Neill, L. A. J., & Pearce, E. J. (2016). Immunometabolism governs dendritic cell and macrophage function. Journal of Experimental Medicine, 213(1), 15–23.

Ott, E., Bilonda, L., Dansette, D., Deleine, C., Duchalais, E., Podevin, J., Volteau, C., Bennouna, J., Touchefeu, Y., Fourquier, P., El Alami Thomas, W., Chetritt, J., Bezieau, S., Denis, M., Toquet, C., Mosnier, J. F., Jarry, A., & Bossard, C. (2019). The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. OncoImmunology.

Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12(4), 265–277.

Palucka, K., & Banchereau, J. (2013). Dendritic-Cell-Based Therapeutic Cancer Vaccines. Immunity, 39(1), 38–48.

Pardoll, D. M., & Topalian, S. L. (1998). The role of CD4+ T cell responses in antitumor immunity. Current Opinion in Immunology, 10(5), 588–594.

Perez, C. R., & De Palma, M. (2019). Engineering dendritic cell vaccines to improve cancer immunotherapy. In Nature Communications.

Phuphanich, S., Wheeler, C. J., Rudnick, J. D., Mazer, M., Wang, H., Nuño, M. A., Richardson, J. E., Fan, X., Ji, J., Chu, R. M., Bender, J. G., Hawkins, E. S., Patil, C. G., Black, K. L., & Yu, J. S. (2013). Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunology, Immunotherapy, 62(1), 125–135.

Rodrigues, C. M., Matias, B. F., Murta, E. F. C., & Michelin, M. A. (2011). The Role of T Lymphocytes in Cancer Patients Undergoing Immunotherapy with Autologous Dendritic Cells. Clinical Medicine Insights: Oncology, 5, CMO.S6927.

Roland, C. L., Dineen, S. P., Lynn, K. D., Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S., & Brekken, R. A. (2009). Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Molecular Cancer Therapeutics, 8(7), 1761–1771.

Sabado, R. L., Balan, S., & Bhardwaj, N. (2017). Dendritic cell-based immunotherapy. In Cell Research.

Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004). C entral M emory and E ffector M emory T C ell S ubsets : Function, Generation, and Maintenance . Annual Review of Immunology.

Sallusto, F., & Lanzavecchi, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus iuterleukin 4 and downregulated by tumor necrosis factor α. Journal of Experimental Medicine.

Seledtsov, V., Goncharov, A., & Seledtsova, G. (2015). Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Human Vaccines & Immunotherapeutics, 11(4), 851–869.

Shangguan, A., Shang, N., Figini, M., Pan, L., Yang, J., Ma, Q., Hu, S., Eresen, A., Sun, C., Wang, B., Velichko, Y., Yaghmai, V., & Zhang, Z. (2020). Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. Cytotherapy, 22(1), 6–15.

Simon, T., Fonteneau, J.-F., & Grégoire, M. (2009). Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy, 1(2), 289–302.

Stanton, S. E., & Disis, M. L. (2016). Clinical significance of tumor-infiltrating lymphocytes in breast cancer.

Tindemans, I., Serafini, N., DiSanto, J. P., & Hendriks, R. W. (2014). GATA-3 function in innate and adaptive immunity. In Immunity.

Töpfer, K., Kempe, S., Müller, N., Schmitz, M., Bachmann, M., Cartellieri, M., Schackert, G., & Temme, A. (2011). Tumor Evasion from T Cell Surveillance. Journal of Biomedicine and Biotechnology, 2011, 1–19.

Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W. H., Pagès, F., & Galon, J. (2011). Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Research.

Vik-Mo, E. O., Nyakas, M., Mikkelsen, B. V., Moe, M. C., Due-Tønnesen, P., Suso, E. M. I., Sæbøe-Larssen, S., Sandberg, C., Brinchmann, J. E., Helseth, E., Rasmussen, A.-M., Lote, K., Aamdal, S., Gaudernack, G., Kvalheim, G., & Langmoen, I. A. (2013). Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunology, Immunotherapy, 62(9), 1499–1509.

Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020). Dendritic cells in cancer immunology and immunotherapy. In Nature Reviews Immunology (Vol. 20, Issue 1, pp. 7–24). Nature Research.

Zong, J., Keskinov, A. A., Shurin, G. V., & Shurin, M. R. (2016). Tumor-derived factors modulating dendritic cell function. Cancer Immunology, Immunotherapy, 65(7), 821–833.




How to Cite

VIEIRA, J. F.; MURTA, E. F. C. .; MICHELIN, M. A. . Prophylactic dendritic cell vaccination in antitumor immune response and tumor growth in a breast cancer mouse model . Research, Society and Development, [S. l.], v. 10, n. 13, p. e100101320905, 2021. DOI: 10.33448/rsd-v10i13.20905. Disponível em: Acesso em: 6 dec. 2021.



Health Sciences